Bayer Subsidiary BlueRock Therapeutics Starts Phase 1 Trial in Patients with Advanced Parkinson’s Disease

Dienstag, 18.01.2022 14:20 von PLX

• (PLX AI) – Bayer subsidiary BlueRock Therapeutics announces first patient dosed in Canada in Phase 1 Trial for Advanced Parkinson’s Disease.
• • It's an open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease
• • The purpose of the Phase 1 clinical trial is to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with Parkinson’s disease